The short answer
In the trials that tracked it, most people regain a large share of the weight within a year of stopping: participants who stopped semaglutide regained about two-thirds of what they had lost (STEP 1 extension), and participants who stopped tirzepatide regained an average of 14% of their body weight (SURMOUNT-4).
“Ozempic rebound” is the most searched fear about these drugs: if I stop taking it, will I gain all the weight back? Is it even worse than before? The anxiety is understandable. These medications produce the most dramatic weight loss most people have ever experienced, and the idea of losing that is frightening.
The answer is uncomfortable but not hopeless. Yes, most people do regain most of the weight. No, it is not worse than before: you return toward your pre-treatment biology, not past it. The medication was actively overriding your appetite hormones. When it stops, those hormones reassert themselves in most people, and the evidence on that is clear. That is not a character flaw. It is how the physiology works.
But the story is more nuanced than the headlines suggest. The regain is gradual, not instant. Not everything reverses at the same rate, and some health benefits persist longer than the weight loss. There are also strategies that make a meaningful difference to outcomes, especially if you start them before you stop the medication rather than after. Here's the full picture from the withdrawal trial data.
The first few weeks after stopping
Wegovy (semaglutide) — the active ingredient in both Ozempic and Wegovy — has a half-life of roughly one week. That is how long the body takes to clear half a dose. Clearing the drug from your system takes five to seven half-lives, so approximately five to seven weeks after the last dose. For daily oral medications, clearance happens much faster, often within days. During this window, the appetite-suppressing effects wind down gradually rather than switching off instantly.
The first thing most people notice is hunger returning, often more intensely than they expected. GLP-1 drugs work on two fronts. They act on receptors in the brain’s hypothalamus to reduce the sensation of hunger. And they slow gastric emptying, which is how fast the stomach empties, so food stays there longer and keeps you fuller. When the drug wears off, both effects reverse. Many people describe “food noise” returning. That is the constant background awareness of food, the intrusive thoughts about what to eat next, the pull toward snacking. It had gone quiet on the medication.
In weeks two to four, cravings tend to intensify. Without the GLP-1 signal dampening the brain’s reward response to food, high-calorie, very tasty foods become appealing again in ways they may not have been for months. Portion sizes start creeping back up. That often happens without conscious awareness, because the fullness signals that would have stopped you earlier are no longer as strong.
See this as a week-by-week timeline
Weeks 1–2
Hunger and food noise return
Appetite suppression fades as the drug clears the system. The constant background thoughts about eating — food noise — come back for most people.
Weeks 2–4
Cravings intensify
The brain's reward response to food normalises without the GLP-1 signal dampening it. Portions begin to creep up, often without conscious awareness.
Months 1–3
Weight starts climbing — fastest period
This is where most regain happens. The metabolic rate adjusts as caloric intake rises. In the STEP 1 follow-up, the majority of regain occurred within the first six months.
Months 3–6
Regain continues but slows
The rate of weight regain typically eases after the initial surge. Most people have not yet reached their original pre-treatment weight at this stage.
Month 12
Most regain has occurred
STEP 1: approximately two-thirds of lost weight regained. SURMOUNT-4: average 14% regain. The trajectory flattens — most of what will be regained has been regained by the one-year mark.
The weight regain timeline — what the trials show
The STEP 1 extension trial followed people for one year after they stopped Wegovy. Participants who stopped regained approximately two-thirds of the weight they had lost during the 68-week treatment period. The regain was sharpest in the first three to six months, then slowed. But it did not stop. By the one-year mark, the average participant had reclaimed most of what the medication had helped them lose.
SURMOUNT-4, which studied Zepbound (tirzepatide), told a similar story from a different angle. Participants first lost weight for 36 weeks on Zepbound, then were randomly assigned to either continue the drug or switch to placebo for a further 52 weeks. Those who stopped Zepbound regained an average of 14% of their body weight over that year. Those who continued lost an additional 5.5%. Only 16.6% of people who stopped maintained 80% or more of their weight loss. That means roughly 5 out of 6 experienced substantial regain.
What this looks like in real numbers
In concrete terms: if you lost 50 lbs on semaglutide, the trial data suggests you would typically regain around 33 lbs within a year of stopping. If you lost 50 lbs on tirzepatide, you would regain roughly 30 lbs based on the SURMOUNT-4 data. These trials studied different populations under different conditions, so exact comparisons are approximate.
Most people do not regain 100% of the weight, at least not within the first year. The trajectory is clearly upward, but it is not a cliff. There is a real window in the months immediately after stopping where lifestyle anchors can significantly influence the outcome.
~2/3
weight regained
STEP 1 follow-up · 1 year after stopping semaglutide
14%
average regain
SURMOUNT-4 · 52 weeks after stopping tirzepatide
16.6%
maintained 80%+ of loss
SURMOUNT-4 · only 1 in 6 after stopping
What comes back — and what doesn’t
More on how appetite, weight and metabolic markers change, in prose
Weight is the most visible thing that returns, but it is not the only thing that changes when you stop. Within one to two weeks, appetite and food noise return. Those are the most immediate signals, because they depend directly on the drug being present. Cravings and the reward response to food normalise over the following weeks. By the three-month mark, body weight is typically climbing noticeably. Some blood-test measures also begin to shift back toward pre-treatment levels as the weight returns: blood sugar, triglycerides and inflammatory markers.
The heart-health trial behind the "partially retained" figure below
What partially persists is more interesting. The SELECT trial followed 17,604 participants with established heart disease. It showed that semaglutide reduced major heart events by 20% over roughly three to four years. The analysis suggested this heart benefit was partly independent of the amount of weight lost. In other words, the drug appeared to protect the heart directly, beyond simply reducing body weight. How much of that persists after stopping is not yet fully understood. But it suggests that periods of treatment may leave lasting biological changes that outlast the weight loss itself.
More on behavioural patterns, in prose
Behavioural changes are the wildcard. Habits you built during treatment can persist if you actively maintain them: smaller portions, more intentional eating, regular exercise, a different relationship with food. This is the primary factor separating the roughly 17% who maintain their weight loss from the 83% who do not. It requires ongoing effort. But the treatment period creates a real opportunity to establish patterns that exist independently of the drug.
There is also an emotional dimension that often goes undiscussed. Many people describe a grief process when stopping. The relief from constant food noise, the transformed relationship with eating, the confidence that came with the weight loss: these are real, meaningful changes in daily life. Losing them is a loss. Acknowledging that makes it easier to plan realistically for the transition.
Comes back (weeks to months)
Appetite and food noise
Returns within 1–2 weeks as the GLP-1 signal that suppresses appetite clears the system. Often described as more intense than expected after months of quiet.
Body weight
Gradual over 6–12 months. In clinical trials, approximately two-thirds of lost weight regained within a year (semaglutide) and an average of 14% over 52 weeks (tirzepatide).
Metabolic markers
Blood sugar, blood pressure and lipids tend to revert toward pre-treatment levels as weight returns. Most of these benefits were weight-dependent.
Partially retained
Heart health improvements
The SELECT trial showed a 20% reduction in major heart events that was partly independent of weight lost. That suggests the drug protects the heart directly, beyond weight change.
Behavioural patterns
Habits formed during treatment can persist if actively maintained: eating awareness, portion intuition, exercise routines. This is the primary predictor of long-term maintenance.
Strategies that make a real difference
If you have to stop, there are practical steps that change the outcome. The reason might be cost, side effects, a planned break, or anything else. None of them guarantees zero regain. The biology is what it is. But the difference between people who maintain most of their weight loss and those who regain it quickly comes down to a handful of factors. Most of those can be influenced.
The most important timing point: start all of this before you stop the medication, not after. When you are still on the drug, appetite is suppressed, food decisions feel manageable, and building habits is far easier. Waiting until you have stopped is starting on hard mode, with food noise back and cravings intensifying.
Taper gradually
Reducing the dose over weeks or months, rather than stopping abruptly, gives your body more time to adjust as the drug’s effects fade. There is no large formal trial comparing tapering with stopping abruptly. But gradual reduction is common clinical practice. The slower the appetite signals return, the more time you have to adjust eating patterns consciously rather than reacting to sudden hunger. Discuss a tapering plan with your prescribing doctor before stopping.
Switch to a cheaper medication rather than stopping entirely
If cost is driving the decision, stopping GLP-1 treatment entirely is not the only option. Oral Wegovy (semaglutide pill) costs $149–$299/month by dose. Injectable Wegovy self-pay is $349–$399/mo ($1,349/month list price). The pill produced 13.6% average weight loss in the OASIS 4 trial. Foundayo (orforglipron), FDA-approved in April 2026, is priced at $149–$349/month. Qsymia (phentermine/topiramate) works through a different mechanism. It costs $30–$80/month and provides meaningful weight management for many people. Maintaining some level of medication support is almost always better than stopping abruptly if weight maintenance is the goal.
Maximise protein and resistance training — before you stop
Across every weight loss maintenance study, with and without medication, resistance training and high protein intake are the two lifestyle factors with the strongest evidence. A target of 1.2–1.6g of protein per kg of body weight per day supports muscle retention, promotes fullness, and has a higher thermic effect than carbohydrate or fat. Regular resistance training preserves muscle, which helps maintain resting metabolic rate. That rate is one of the key things that changes during weight loss and makes regain easier. Starting or intensifying both while still on medication, rather than after stopping, gives the strongest foundation.
One more strategy: build your support structure in advance
Build your support structure in advance
The transition off GLP-1 medication is as much psychological as it is physiological. Having a doctor or nurse practitioner who understands what you’re going through makes a measurable difference, rather than one who dismisses food noise as “just willpower”. Several other things contribute to better outcomes. A registered dietitian familiar with coming off GLP-1s. A therapist or support community for the emotional side. And clear monitoring checkpoints, such as monthly weight checks and dietary review. The people who maintain their weight loss have them. The people who regain quickly often do not.
Regain is not failure: When medication stops, appetite hormones return to pre-treatment levels. That is the expected biological response. It is not a sign that something went wrong or that the treatment “didn’t work.” We do not blame people with high blood pressure when their readings go up after they stop their blood pressure pills. Obesity is a chronic condition with the same logic: the treatment worked while it was active. The question is what you do next, not what the regain says about you.
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: